Original Article
Outcome of allogeneic hematopoietic stem-cell transplantation for 16 patients with myeloid sarcoma
Ye Zhao, Jia Chen, Xiao Ma, Yue Han, Xiaowen Tang, Huiying Qiu, Depei Wu
Published 2018-09-30
Cite as Chin J Metastatic Cancer, 2018, 01(2): 30-34. DOI: 10.3760/cma.j.issn.2096-5400.2018.02.007
Abstract
ObjectiveTo evaluate the efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in patients with myeloid sarcoma (MS).
MethodsThe therapeutic effect of allo-HSCT on 16 patients with MS in our center was retrospectively analyzed. Among them, 5 patients were diagnosed as isolated MS, 10 patients were MS presenting with acute myeloid leukemia(AML)and 1 was accompanied with myelodysplastic syndrome/myeloproliferative neoplasm(MDS/MPN).
ResultsAll of the 16 patients were diagnosed as MS by pathological biopsies. Patients were initially treated with chemotherapy and then allo-HSCT. Hematopoiesis reconstitution was achieved in all the patients, with a median follow-up time of 36(4-106)months after transplantation, 7 patients died. The 3-year overall survival(OS) was 54.17%. Six patients(37.5%)relapsed after allo-HSCT, and the relapse was the major cause of death.
ConclusionsAllo-HSCT is an effective therapeutic option for patients with MS.
Key words:
Allogeneic hematopoietic stem cell transplantation; Myeloid sarcoma; Outcome
Contributor Information
Ye Zhao
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, China
Jia Chen
Xiao Ma
Yue Han
Xiaowen Tang
Huiying Qiu
Depei Wu
